---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-031419"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-09-29T12:45:26+00:00"
generated_at: "2026-10-12T13:43:45.973347+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech completes Part A enrollment in Phase 2/3 MIRACLE trial with 89 R/R AML subjects

## Summary
- Part A of the pivotal Phase 2/3 MIRACLE trial closed enrollment with 89 subjects enrolled and one additional subject in screening.
- Moleculin remains on track for a comprehensive Part A data readout in Q1 2027.
- The full Part A population is expected to be approximately 50/50 between 1L 7+3 and venetoclax-based regimens, versus a 70/30 split in the first 45 subjects.
- CEO Walter Klemp said the Q1 2027 readout will be deeper in data than the first interim n45 readout.
- The company continues to see no cardiotoxicity in blinded MIRACLE data; AnnAraC combines Annamycin with cytarabine.

## SEC filing metadata
- accession: 0001437749-26-031419
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-09-29T12:45:26+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926031419/0001437749-26-031419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926031419/mbrx20260928_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-031419
- JSON: https://secwatch.observer/filing/0001437749-26-031419.json
- Plain text: https://secwatch.observer/filing/0001437749-26-031419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.